ClinicalTrials.gg

Arthritis, Rheumatoid clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,336 studies for Arthritis, Rheumatoid across more than 10 countries. 445 are recruiting or about to start. 2,807 of them are mainly about Arthritis, Rheumatoid (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Sjogren's Syndrome: 3,641 studies, 524 open.

ClinicalTrials.gov finds 3,814 studies for Arthritis, Rheumatoid. How that becomes 3,334 here

This page counts the studies the registry files under Arthritis, Rheumatoid, and those it files under no condition that list Arthritis, Rheumatoidthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 3,814Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −296Filed under a narrower condition, counted on its own pageSjogren's Syndrome 276 · Still's Disease, Adult-Onset 20
  3. −56List Arthritis, Rheumatoid as a condition, but the registry did not file them under itMost often written as “Juvenile Rheumatoid Arthritis” (18), “Rheumatoid Arthritis of Knee” (8), and “Rheumatoid Arthritis Shoulder” (5). The registry filed them under other conditions only, most often Arthritis, Juvenile (23) and Arthritis (10).
  4. −128Match it another way82 name it in the title, 12 in a keyword, and 34 by a synonym or other text the search reads.
  5. 3,334The count on this page44 of them list Arthritis, Rheumatoid in their own words; the registry filed them under no condition.

Status

Completed
2,067
Status unknown
356
Recruiting
293
Terminated
266
Not yet recruiting
127
Active, not recruiting
116

Phase

Phase 2
576
Phase 3
460
Phase 1
389
Phase 4
327
Early Phase 1
18

Where

United States
975
Germany
361
France
357
United Kingdom
314
Poland
290
Spain
265

Who develops what

Add Arthritis, Rheumatoid to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 73 programs from 50 companies, 49 with this as their studies’ main aim; 2 with a live phase 3 study; 12 primary completions in the next 12 months. Compare AbbVie, Bristol-Myers Squibb and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
MethotrexateRecent, repeated
Evidence
  • NCT07895524 · Merck & Co., Inc · Phase 2 · live · background · “Methotrexate (MTX)” · registered Oct 2026
  • NCT07176390 · Merck & Co., Inc · Phase 2 · live · background · “Methotrexate” · registered Sep 2025
  • NCT06800157 · Shanghai Longwood Biopharmaceuticals Co., Ltd. · Phase 2 · background · “MTX” · registered Oct 2024
  • NCT06590090 · xbiotech inc · Phase 2 · live · background · “Methotrexate (MTX)” · registered Aug 2024
  • NCT06048224 · Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 3 · comparator · “Actemra +MTX” · registered Sep 2023
Hoffmann-La Roche28% of its industry studiesUS: off-patent, 21 generics marketedEU: Nordic Group B.V. (EMA 2016) + 1 other56 studies
tocilizumabRecent, repeated
Evidence
  • NCT06475508 · AO GENERIUM · Phase 3 · comparator · “Actemra®” · registered Jun 2024
  • NCT06048224 · Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 3 · comparator · “Actemra +MTX” · registered Sep 2023
  • NCT03830203 · Bio-Thera Solutions · Phase 3 · comparator · “Actemra(EU-licensed)” · registered Jan 2019
  • NCT03737708 · Astellas Pharma Inc · Phase 4 · background · “tocilizumab” · registered Nov 2018
  • NCT02287922 · Sanofi · Phase 2 · comparator · “Tocilizumab” · registered Nov 2014
Hoffmann-La Roche89% of its industry studiesUS: Hoffmann-La Roche (FDA 2010) + 3 othersEU: Hoffmann-La Roche (EMA 2009) + 4 others22 studies
tofacitinibRecent, repeated
Evidence
  • NCT06020144 · Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3 · comparator · “Tofacitinib” · registered Aug 2023
  • NCT05165771 · Gilead Sciences · Phase 2 · comparator · “Tofacitinib 5 mg” · registered Dec 2021
  • NCT05133297 · Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 2 · comparator · “Tofacitinib” · registered Nov 2021
Pfizer94% of its industry studiesUS: off-patent, 23 generics marketedEU: Pfizer (EMA 2017)22 studies

27 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
TLL-018☆ Track1 live phase-3 study: NCT06887127Hangzhou Highlightll Pharmaceutical Co., Ltd
Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection☆ Track1 live phase-3 study: NCT06726096Beijing VDJBio Co., LTD.

The 2 in phase 3 with the nearest primary completion, of 73 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (12)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.TOLLB-001 · Toll Biotech Co. Ltd. (Beijing) · Phase 2 main aimNCT07408024 Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis — primary endpoint: Safety-AE/lab tests/PE/VS/ECG · 24 enrolled
  • 31 Dec 2026 est.TLL-018 · Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3 main aimNCT06887127 A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis — primary endpoint: Number of occurrences and Percentage of Participants with AEs and SAEs · 350 enrolled
  • Feb 2027 est.lutikizumab, ravagalimab · AbbVie · Phase 2 main aimNCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis — primary endpoint: Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response · 180 enrolled

9 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Arthritis, Rheumatoid studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 17 open · JAK inhibitors 17 open · Antimetabolites 9 open · Antihistamines 4 open · SGLT2 inhibitors 3 open

Coming up

139studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger. 15 (5%) take children under 18. 7 (2%) are for women only and 2 (1%) for men only; 36 (12%) take healthy volunteers.

Recruiting studies that take each age, of 293
AgeWomenMen
1011 (4%)10 (3%)
18258 (88%)253 (86%)
30283 (97%)278 (95%)
40286 (98%)281 (96%)
50288 (98%)284 (97%)
65271 (92%)269 (92%)
75214 (73%)213 (73%)
85171 (58%)170 (58%)

Across all 3,336 studies, recruiting or not: 30% stop at 75 or younger and 13% at 65; 6% take children; 3% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Arthritis, Rheumatoid studies take

Of 158 phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 116 mo5–32 · 148 studies13 mo5–32 · 128 studies—
Phase 1/222 mo12–26 · 29 studies——
Phase 218 mo13–30 · 158 studies17 mo13–24 · 116 studies43 mo13–49 · 42 studies
Phase 326 mo17–40 · 148 studies24 mo16–31 · 116 studies—
Phase 442 mo25–74 · 104 studies26 mo16–44 · 25 studies49 mo30–92 · 79 studies
Interventional, no phase27 mo13–51 · 348 studies61 mo26–92 · 56 studies24 mo12–39 · 292 studies
Observational50 mo25–113 · 391 studies60 mo32–113 · 155 studies43 mo19–122 · 236 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered14

Show 9 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,336. Browse all 3,336 → or search them.